Search results
Results From The WOW.Com Content Network
July 30, 2024 at 4:04 AM. Wall Street's concerns about GLP-1s' impact on medical device makers was back in full swing after glucose monitoring device seller Dexcom ( DXCM) slashed its full-year ...
So we will have to play." But at the same time, Bourla ruled out an acquisition for a company that already has a promising GLP-1 drug. And the simple reason is that Pfizer is already coming off a ...
Analysts expect Ozempic and Wegovy combined to bring in sales of $26 billion for Novo for the full year 2024, and Mounjaro and Zepbound could net Lilly about $13.5 billion, according to Bloomberg ...
Alcon offices in Johns Creek, Georgia. Alcon Inc. ( German: Alcon AG) is a Swiss-American pharmaceutical and medical device company specializing in eye care products. It has a paper headquarters in Geneva, Switzerland but its operational headquarters are in Fort Worth, Texas, United States, where it employs about 4,500 people. [2]
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc., a subsidiary of AstraZeneca, is a pharmaceutical company headquartered in Boston, Massachusetts that specializes in orphan drugs to treat rare diseases . Its products include eculizumab (Soliris) and ravulizumab (Ultomiris), both used to treat the rare disorders of atypical hemolytic ...
July 10, 2024 at 3:41 AM. Altimmune (NASDAQ: ALT) and Viking Therapeutics (NASDAQ: VKTX) are a pair of biotechs planning to follow in the footsteps of Novo Nordisk and Eli Lilly and develop GLP-1 ...
The following table lists the largest biotechnology and pharmaceutical companies ranked by market capitalization in billion US dollars. The change column indicates the company's relative position in this list compared to their relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
July 11, 2024 at 6:07 PM. PepsiCo ( PEP) CEO Ramon Laguarta said GLP-1 drugs for weight loss and diabetes, such as Ozempic, Wegovy, and Mounjaro, aren't yet having an effect on the business. In ...